Axitinib

Axitinib, sold under the brand name Inlyta, is a small molecule tyrosine kinase inhibitor developed by Pfizer. It has been shown to significantly inhibit growth of breast cancer in animal (xenograft) models[3] and has shown partial responses in clinical trials with renal cell carcinoma (RCC)[4] and several other tumour types.[5] It was approved to treat renal cell carcinoma by the U.S. Food and Drug Administration after showing a modest increase... [wikipedia]